PMID- 25607705
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20220311
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 13
IP  - 11
DP  - 2014 Nov
TI  - Real-life treatment profile of calcipotriene and betamethasone dipropionate 
      topical suspension in patients with psoriasis vulgaris.
PG  - 1374-9
AB  - BACKGROUND: Treatment with calcipotriene plus betamethasone dipropionate (CBD) 
      fixed-combination topical suspension has been shown to be effective and well 
      tolerated in patients with psoriasis vulgaris. AIM: To document experiences with 
      CBD topical suspension in a US clinical dermatology setting using 
      patient-reported outcomes (PROs). METHODS: In total, 147 patients were enrolled 
      in this 8-week, prospective, noninterventional, multicenter, one-arm study. Data 
      were collected at baseline and week 8 at the office, and at one time at home 
      (week 2). PROs were assessed using the Dermatology Life Quality Index (DLQI), 
      Patient's Global Assessment of disease severity (PtGA) using a 5-point Likert 
      scale, patient-reported level of itching using a 0-100 graduated visual analog 
      scale, and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). 
      Treatment adherence and adverse events (AEs) were assessed at week 8. RESULTS: 
      After 8 weeks of treatment, DLQI score significantly improved compared with 
      baseline (-5.5 +/- 5.93; P<.0001), starting as early as week 2 (-4.2 +/- 5.28; 
      P<.0001). The level of itching was significantly reduced from baseline to week 2 
      (-19% +/- 25.94%; P<.0001) and week 8 (-28.6% +/- 29.14%; P<.0001). The percentage of 
      patients with "controlled disease" (PtGA score of "clear" or "very mild") was 
      34.1% at week 2 and 60.2% at week 8. At the end of treatment, mean TSQM-9 scores 
      for effectiveness, convenience, and satisfaction domains ranged from 68 to 74. 
      Patients reported the need to use CBD topical suspension for an average of 53.62 
      +/- 8.05 days. Treatment-emergent AEs occurred in 3 patients. CONCLUSION: The 
      results of this noninterventional study are consistent with previously reported 
      data from interventional trials and suggest that treatment with CBD topical 
      suspension is efficacious and well tolerated and improves quality of life in 
      patients with psoriasis vulgaris.
FAU - Bagel, Jerry
AU  - Bagel J
FAU - Levi, Eugenia
AU  - Levi E
FAU - Tyring, Stephen
AU  - Tyring S
FAU - Knuckles, Melissa L F
AU  - Knuckles ML
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Suspensions)
RN  - 143NQ3779B (calcipotriene)
RN  - 826Y60901U (betamethasone-17,21-dipropionate)
RN  - 9842X06Q6M (Betamethasone)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Betamethasone/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Calcitriol/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Prospective Studies
MH  - Pruritus/drug therapy/etiology
MH  - Psoriasis/*drug therapy/pathology
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Suspensions
MH  - Treatment Outcome
EDAT- 2015/01/22 06:00
MHDA- 2015/09/29 06:00
CRDT- 2015/01/22 06:00
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - S1545961614P1374X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2014 Nov;13(11):1374-9.